Cynthia Madden

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 368 citations

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 276 citations

Systemic Treatment, Clinical Trials, Bimekizumab Versus Ustekinumab +6

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B. Gordon, Peter Foley, James G. Krueger et al. · The Lancet · 2021 · 258 citations

Systemic Treatment, Bimekizumab Efficacy, Clinical Trials +6

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed et al. · The Lancet · 2024 · 128 citations · Full text

Moderate-to-severe Hidradenitis Suppurativa, Be Heard Ii, Be Heard +3

Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study

Andrew Blauvelt, Kim Papp, Joseph F. Merola et al. · Journal of the American Academy of Dermatology · 2020 · 60 citations